We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current ANAB market cap is 572.19M. The company's latest EPS is USD -4.8098 and P/E is -4.45.
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 1.29M | 6.81M | 1.37M | 3.46M | 3.32M |
Operating Income | -29.63M | -25.97M | -44.4M | -40.14M | -37.73M |
Net Income | -33.5M | -26.41M | -44.26M | -39.85M | -37.31M |
Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 5M | 8M | 75M | 63.18M | 10.29M |
Operating Income | -66.72M | -107.43M | -23.88M | -56.81M | -115.15M |
Net Income | -61.66M | -97.34M | -19.93M | -57.8M | -128.72M |
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 618.5M | 610.38M | 551.79M | 517.1M | 487.33M |
Total Liabilities | 340.88M | 348.28M | 360.7M | 368.65M | 366.94M |
Total Equity | 277.62M | 262.1M | 191.09M | 148.45M | 120.38M |
Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 509M | 435.2M | 416.55M | 643.07M | 610.38M |
Total Liabilities | 22.63M | 30.19M | 19.82M | 286.64M | 348.28M |
Total Equity | 486.37M | 405.01M | 396.73M | 356.43M | 262.1M |
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -62.91M | -73.59M | -24.57M | -49.98M | -86.45M |
Investing | -416.34M | -394.85M | 85.4M | 64.94M | 95.58M |
Financing | 42.07M | 44.02M | -37.57M | -51.07M | -54.14M |
Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -48.51M | -69.52M | -14.16M | -45.92M | -73.59M |
Investing | -142.45M | 131.43M | 94.48M | 38.84M | -394.85M |
Financing | 223.36M | -4.49M | -879k | 252.3M | 44.02M |
Market Cap | 572.19M |
Price to Earnings Ratio | -4.45 |
Price to Sales Ratio | 55.62 |
Price to Cash Ratio | 8.02 |
Price to Book Ratio | 2.18 |
Dividend Yield | - |
Shares Outstanding | 26.76M |
Average Volume (1 week) | 463.18k |
Average Volume (1 Month) | 387.65k |
52 Week Change | -2.15% |
52 Week High | 27.50 |
52 Week Low | 13.36 |
Spread (Intraday) | 18.99 (55.87%) |
Company Name | AnaptysBio Inc |
Address |
1209 orange street wilmington, delaware 19801 |
Website | https://www.anaptysbio.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions